Is TransMedics Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for TransMedics Group, Inc. has moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key valuation ratios include a P/E ratio of 96, an EV to EBITDA of 66.22, and a PEG ratio of 0.53, indicating a potential for growth relative to its price.
In comparison to its peers, TransMedics Group, Inc. has a P/E ratio of 50.23, which is significantly lower than iRhythm Technologies, Inc. with a P/E of -111.60 and Axonics, Inc. with a P/E of 492.77, suggesting that TransMedics is more attractively priced within its industry. Additionally, the company has demonstrated strong performance with a YTD return of 88.66%, significantly outperforming the S&P 500's return of 13.30% over the same period, reinforcing its favorable valuation position.